Annovis Bio, Inc.

ANVS Healthcare Biotechnology

In the quarter to June 2026, EPS fell 25.0% and free cash flow fell 329.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.99 0.06 −5.71%
Market cap
$44.8M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(246.14%) (220.61%) (301.13%) (703.68%)
ROA
(157.74%) (164.85%) (190.43%) (227.74%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(184.94%) (165.39%) (1,185.13%) (315.88%)
Average Days of Receivables
— — — —
Free Cash Flow per Share
(1.27) (1.25) (0.95) (1.16)
Free Cash Flow
(24.98) (25.62) (26.53) (43.34)
Other line items

Show all line items

Columns are period end dates